11/27/2013

Crohn's disease patients taking adalimumab following intestinal resection had a lower risk of disease recurrence, compared with those taking the traditional drugs azathioprine and mesalamine, Italian researchers report in The American Journal of Gastroenterology. Data also showed patients taking adalimumab had higher quality of life scores.

Related Summaries